Sitagliptin: a potential drug for the treatment of COVID-19?
Recently, an outbreak of a fatal coronavirus, SARS-CoV-2, has emerged from China and is rapidly spreading worldwide. Possible interaction of SARS-CoV-2 with DPP4 peptidase may partly contribute to the viral pathogenesis. An integrative bioinformatics approach starting with mining the biomedical lite...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sciendo
2021-06-01
|
| Series: | Acta Pharmaceutica |
| Subjects: | |
| Online Access: | https://doi.org/10.2478/acph-2021-0013 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832572164721606656 |
|---|---|
| author | Bardaweel Sanaa K. Hajjo Rima Sabbah Dima A. |
| author_facet | Bardaweel Sanaa K. Hajjo Rima Sabbah Dima A. |
| author_sort | Bardaweel Sanaa K. |
| collection | DOAJ |
| description | Recently, an outbreak of a fatal coronavirus, SARS-CoV-2, has emerged from China and is rapidly spreading worldwide. Possible interaction of SARS-CoV-2 with DPP4 peptidase may partly contribute to the viral pathogenesis. An integrative bioinformatics approach starting with mining the biomedical literature for high confidence DPP4-protein/gene associations followed by functional analysis using network analysis and pathway enrichment was adopted. The results indicate that the identified DPP4 networks are highly enriched in viral processes required for viral entry and infection, and as a result, we propose DPP4 as an important putative target for the treatment of COVID-19. Additionally, our protein-chemical interaction networks identified important interactions between DPP4 and sitagliptin. We conclude that sitagliptin may be beneficial for the treatment of COVID-19 disease, either as monotherapy or in combination with other therapies, especially for diabetic patients and patients with pre-existing cardiovascular conditions who are already at higher risk of COVID-19 mortality. |
| format | Article |
| id | doaj-art-e18775000ced4ffea2513a667f9d48fd |
| institution | Kabale University |
| issn | 1846-9558 |
| language | English |
| publishDate | 2021-06-01 |
| publisher | Sciendo |
| record_format | Article |
| series | Acta Pharmaceutica |
| spelling | doaj-art-e18775000ced4ffea2513a667f9d48fd2025-02-02T11:49:57ZengSciendoActa Pharmaceutica1846-95582021-06-0171217518410.2478/acph-2021-0013acph-2021-0013Sitagliptin: a potential drug for the treatment of COVID-19?Bardaweel Sanaa K.0Hajjo Rima1Sabbah Dima A.2Department of Pharmaceutical Sciences School of Pharmacy, University of Jordan, Amman11942, JordanDepartment of Pharmacy, Faculty of Pharmacy, Al-Zaytoonah University of Jordan, P.O. Box 130, Amman 11733JordanDepartment of Pharmacy, Faculty of Pharmacy, Al-Zaytoonah University of Jordan, P.O. Box 130, Amman 11733JordanRecently, an outbreak of a fatal coronavirus, SARS-CoV-2, has emerged from China and is rapidly spreading worldwide. Possible interaction of SARS-CoV-2 with DPP4 peptidase may partly contribute to the viral pathogenesis. An integrative bioinformatics approach starting with mining the biomedical literature for high confidence DPP4-protein/gene associations followed by functional analysis using network analysis and pathway enrichment was adopted. The results indicate that the identified DPP4 networks are highly enriched in viral processes required for viral entry and infection, and as a result, we propose DPP4 as an important putative target for the treatment of COVID-19. Additionally, our protein-chemical interaction networks identified important interactions between DPP4 and sitagliptin. We conclude that sitagliptin may be beneficial for the treatment of COVID-19 disease, either as monotherapy or in combination with other therapies, especially for diabetic patients and patients with pre-existing cardiovascular conditions who are already at higher risk of COVID-19 mortality.https://doi.org/10.2478/acph-2021-0013sars-cov-2covid-19dpp4ace2sitagliptindrug repurposingcxcl10 |
| spellingShingle | Bardaweel Sanaa K. Hajjo Rima Sabbah Dima A. Sitagliptin: a potential drug for the treatment of COVID-19? Acta Pharmaceutica sars-cov-2 covid-19 dpp4 ace2 sitagliptin drug repurposing cxcl10 |
| title | Sitagliptin: a potential drug for the treatment of COVID-19? |
| title_full | Sitagliptin: a potential drug for the treatment of COVID-19? |
| title_fullStr | Sitagliptin: a potential drug for the treatment of COVID-19? |
| title_full_unstemmed | Sitagliptin: a potential drug for the treatment of COVID-19? |
| title_short | Sitagliptin: a potential drug for the treatment of COVID-19? |
| title_sort | sitagliptin a potential drug for the treatment of covid 19 |
| topic | sars-cov-2 covid-19 dpp4 ace2 sitagliptin drug repurposing cxcl10 |
| url | https://doi.org/10.2478/acph-2021-0013 |
| work_keys_str_mv | AT bardaweelsanaak sitagliptinapotentialdrugforthetreatmentofcovid19 AT hajjorima sitagliptinapotentialdrugforthetreatmentofcovid19 AT sabbahdimaa sitagliptinapotentialdrugforthetreatmentofcovid19 |